Macquarie Group becomes substantial holder in Australian Clinical Labs

Macquarie Group Limited, alongside its controlled bodies corporate, has disclosed an initial substantial holding in Australian Clinical Labs Limited, with the status effective from 29 September 2025. The group's total voting power stands at 5.11%, representing 9,995,276 ordinary fully paid (FPO) securities.

Key entities within the Macquarie Group holding relevant interests include Macquarie Bank Limited, Macquarie Investment Management Australia Limited, Macquarie Investment Management Global Limited, Macquarie Investment Management Limited, and Macquarie Investment Services Limited. These interests involve control over disposal, voting rights, and investment management capacities.

The consideration for certain relevant interests acquired in the four months prior to the substantial holder date included an on-market purchase by Macquarie Investment Management Australia Limited of 1,098 FPO securities at AUD 2.44 per security, and a collateral receive transaction by Macquarie Bank Limited for 220,101 FPO securities at AUD 0.00 per security, both on 29 September 2025.